NCT04477512View on ClinicalTrials.gov

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 19, 2021

Primary Completion Date

September 9, 2021

Study Completion Date

September 11, 2025

Conditions
Metastatic Hormone Refractory Prostate Cancer
Interventions
DRUG

Cabozantinib

Supplied by Exelixis

DRUG

Nivolumab

Supplied by Bristol-Myers Squibb

DRUG

Abiraterone acetate

Commercially available

DRUG

Prednisone

Commercially available

PROCEDURE

Peripheral blood collection

Prior to start of treatment, after 8 weeks of combination therapy, with every subsequent imaging (every 12 weeks), end of treatment

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Exelixis

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT04477512 - Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial) | Biotech Hunter | Biotech Hunter